Go to fibryga USA Homepage

When major bleeds don't slow down fibryga stays ahead when urgency takes the lead

Discover the first and only FDA-approved fibrinogen concentrate for bleeding patients with acquired fibrinogen deficiency (AFD), also known as acquired hypofibrinogenemia.1,2

What is AFD?Why Fibryga?

Rapid, Precise, On Hand.1

Rapidly
Reconstituted

Fibrinogen replacement needs arise fast. Fibryga can be reconstituted within 5–10 minutes for rapid hemostasis in emergency and perioperative settings.1,3-7

Consistent &
Precise Dosing

Take the guesswork out of fibrinogen replacement. Each fibryga vial contains ~1 g or ~2 g of fibrinogen concentrate.1

No Refrigeration
Required

No cooling, no thawing.
Unlike some other fibrinogen concentrates, fibryga does not require refrigeration, making it readily available at the point of care.1,8
Get the details

Consistent & Precise Dosing in Every Vial1

Only fibryga provides a consistent and precise amount of purified fibrinogen in a low volume infusion—
~1 g/50 mL or ~2 g/100 mL sterile water solution.1

See how to put
fibryga into action

Fibryga is the precise approach to your bleeding patients with AFD

Dive Into the Non-Clinical Attributes of fibryga and Other AFD Treatment Options:

FibrygaRiastap*CryoCERUS IFC
Reconstituted and/or administered in 5-10 minutes1,8-10checkmarkx†xx
Precise amount of fibrinogen per unit1,5,8,10,11checkmark‡checkmark§xx
Can be stored at room temperature1,8,10,12checkmarkxxcheckmark
Administered without need for ABO matching1,8,10,13,14checkmarkcheckmarkxx
Factor XIII activity >2.5 (Units/mL)10,15,16checkmarkxcheckmark#checkmark
Virally inactivated1,8,10,11checkmarkcheckmarkxcheckmark‖
Supplied with a transfer device that includes a particle filter1,8,10checkmark**xN/Ax
Supplied with a 50 mL (~1 g) or 100 mL (~2 g) vial of diluent (sterile Water for Injection)1,8checkmarkxN/AN/A

cryo=cryoprecipitate.

RiaSTAP® is a registered trademark of CSL Behring GmbH.

INTERCEPT® Fibrinogen Complex, IFC is a registered trademark of Cerus Corporation.

nextaro® is a registered trademark of sfm medical devices GmbH.

*RiaSTAP® is not approved for AFD.

†Must be brought to room temperature prior to reconstitution.

‡Approximately 1 g or 2 g of fibrinogen per vial.

§0.9 g to 1.3 g of fibrinogen per vial.

Once thawed, for up to 5 days.

#Ranges between 2.7‑4.0.

‖Certain non-enveloped viruses (e.g., hepatitis A virus, hepatitis E virus, parvovirus B19, and poliovirus) have demonstrated resistance to the INTERCEPT® process.10

**nextaro® transfer device.

Explore what sets fibryga apart

Around the world,
Guidelines Support Fibrinogen Concentrate

ASA & ACS

Recognize fibrinogen concentrate (FC) as a suitable alternative to cryoprecipitate (cryo) when rapid, precise hemostasis is essential.17,18

SCA

According to an SCA advisory, FC should be considered in adult cardiac surgical patients with low fibrinogen levels and persistent post-CPB bleeding, to reduce bleeding and lower the risk for transfusion.19

ACOG

FC may be preferred over cryo in postpartum hemorrhage to minimize viral transmission risk.20

European Guidelines

Recommend FC or cryo if bleeding is accompanied by hypofibrinogenemia.21,22

ACOG=American College of Obstetricians and Gynecologists; ACS=American College of Surgeons; ASA=American Society of Anesthesiologists; SCA=Society of Cardiovascular Anesthesiologists.

Did you know?

Approved in the US, Europe, UK & Canada

HCPs Around the World Rely on Fibryga to Treat Fibrinogen Deficiency.1,23-25

See the data

Demonstrated SafetyAcross 2 Indications1

Review the data

Have questions aboutfibryga or Octapharma?

connect with a rep

Indications & Important Safety Information for Fibryga, Fibrinogen (Human)

Indications and Usage

Fibryga is a human fibrinogen concentrate indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency and in treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Fibryga is not indicated for dysfibrinogenemia.

Contraindications

Fibryga is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga or its components (Sodium Citrate Dihydrate; Glycine; L-Arginine Hydrochloride).

Warnings and Precautions

Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment.

Thrombotic events have been reported in patients receiving fibryga. Treatment with human fibrinogen concentrate in congenital fibrinogen deficiency has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.

Fibryga is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Reactions

The most serious adverse reactions observed with fibryga are thromboembolic episodes and anaphylactic-type reactions.

The most common adverse reactions observed in clinical studies with fibryga in acquired fibrinogen deficiency (>5% of patients) were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure.

The most common adverse reactions observed in clinical studies with fibryga in congenital fibrinogen deficiency (>5% of patients) were nausea, vomiting, pyrexia (fever) and thrombocytosis.

Please see fibryga full Prescribing Information.

To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.